Pacritinib not only effectively inhibits the growth of many FLT3-ITD+ AML cell lines, but combined inhibition of JAK2 and FLT3 also overcomes the resistance towards FLT3 inhibitors (e.g., Sunitinib), which is often associated with overactivation of the JAK-STAT pathway [137]. Here, SOAT1 is linked to acute myeloid leukemia.